碘对比剂独立于游离碘干扰甲状腺碘摄取
研究通过质谱定量碘对比剂中游离碘、细胞系及表达钠碘同向转运体的小鼠模型,结合SPECT/CT与患者闪烁扫描,发现碘对比剂可降低甲状腺对放射性示踪剂的摄取,该效应不依赖游离碘,而是源于甲状腺细胞钠碘同向转运体蛋白表达的特异性显著下降。
要点
- 碘对比剂中虽含游离碘,但体外实验显示其不显著影响表达钠碘同向转运体细胞的碘摄取。
- 小鼠静脉或舌下给予碘对比剂后甲状腺放射性示踪剂摄取减少,伴钠碘同向转运体蛋白表达显著下降。
- 该效应在人类中亦观察到且为甲状腺选择性;碘化钾则同时降低小鼠甲状腺与唾液腺摄取。
核心结论
- 碘对比剂降低甲状腺碘摄取不依赖游离碘,而是由于甲状腺细胞钠碘同向转运体表达的特异性显著下降。
- 该发现对用尿碘浓度评估碘对比剂给药与分化型甲状腺癌放射性碘治疗间隔的相关性提出严重质疑。
- 碘对比剂干扰甲状腺碘摄取的能力或可用于辐射防护。
研究设计与样本
- 采用质谱分析定量碘对比剂中游离碘污染。
- 使用表达钠碘同向转运体的已建立细胞系定量碘对比剂对碘摄取的影响。
- 采用SPECT/CT测量表达钠碘同向转运体的小鼠甲状腺和唾液腺两种组织对99mTc-高锝酸盐和123I的体内摄取。
- 比较未接受碘对比剂与接受碘对比剂患者的闪烁扫描。
- 进行免疫组织学与蛋白质印迹分析评估这些器官中钠碘同向转运体蛋白表达。
主要发现
- 碘对比剂制剂中虽存在游离碘,但体外表达钠碘同向转运体细胞的碘摄取未受碘对比剂显著影响。
- 小鼠静脉或舌下给予碘对比剂后甲状腺放射性示踪剂摄取减少,伴该组织钠碘同向转运体蛋白表达显著下降。
- 小鼠唾液腺中放射性示踪剂摄取与钠碘同向转运体蛋白表达均未受碘对比剂影响。
- 碘对比剂的甲状腺选择性效应在人类中亦观察到。
- 给予碘化钾作为游离碘来源导致小鼠甲状腺和唾液腺99mTc-高锝酸盐摄取均减少。
临床怎么用
- 作者认为用尿碘浓度评估碘对比剂给药与分化型甲状腺癌放射性碘治疗间隔的相关性存在严重疑问。
- 作者提出碘对比剂干扰甲状腺碘摄取的能力或可用于辐射防护。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Perturbation of thyroid iodide uptake is a well-documented side effect of the use of iodinated contrast media (ICM) administered intravenously. This side effect is thought to be mediated by free iodide in ICM formulations, but this hypothesis has never been formally proven. The aim of the present study was to assess the validity of this hypothesis. Methods: We used mass spectrometry analysis to quantify free-iodide contamination in ICM. Established cell lines expressing the Na/I symporter (NIS) were used to quantify the effect of ICM on iodide uptake. SPECT/CT was used to measure the in vivo uptake of 99mTc-pertechnetate and 123I in 2 NIS-expressing mouse tissues, thyroid and salivary glands. Scintiscans of ICM-naïve and ICM-administered patients were compared. Immunohistologic and Western blot analyses were performed to evaluate NIS protein expression in these organs. Results: Although free iodide was present in ICM formulations, in vitro uptake of iodide by NIS-expressing cells was not significantly affected by ICM. In mice, intravenous or sublingual administration of ICM led to a reduction in radiotracer uptake by the thyroid, accompanied by a dramatic reduction in NIS protein expression in this tissue. In the salivary glands, neither radiotracer uptake nor NIS protein expression was affected by ICM. The thyroid-selective effect of ICM was also observed in humans. Administration of potassium iodide as a source of free iodide led to a diminution of 99mTc-pertechnetate uptake in both mouse thyroid and mouse salivary glands. Altogether, these data rule out a direct intervention of free iodide in the perturbation of thyroid uptake and suggest a direct and selective effect of ICM on the thyroid. Conclusion: We demonstrated that ICM reduce thyroid uptake of iodide independently of free iodide. This effect is due to a specific and dramatic decrease in NIS expression in thyrocytes. These data cast serious doubt on the relevance of measuring urinary iodide concentration to evaluate the delay between ICM administration and radioiodine therapy in patients with differentiated thyroid carcinoma. Finally, the ability of ICM to perturb iodide uptake in the thyroid may be used in radioprotection.
引用
- Vassaux G, Zwarthoed C, Signetti L, et al. Iodinated Contrast Agents Perturb Iodide Uptake by the Thyroid Independently of Free Iodide. J Nucl Med. 2017. PMID: 29051343. doi:10.2967/jnumed.117.195685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。